RecruitingPhase 2NCT05419076

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) From Small Cell Lung Cancer (SCLC)

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

62 participants

Start Date

Jun 10, 2022

Study Type

INTERVENTIONAL

Conditions

Lung Cancer Brain Metastases, Adult Brain Metastases Lung Cancer Metastatic

Summary

The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing stereotactic radiosurgery (SRS) — a highly targeted, high-dose radiation technique — for people with small cell lung cancer that has spread to the brain. It is testing whether SRS can effectively treat multiple brain metastases (up to 20 spots) while minimizing side effects compared to whole-brain radiation. **You may be eligible if...** - You have been diagnosed with small cell lung cancer - You have up to 20 brain metastases visible on MRI scan - You are 18 or older - You are in reasonably good physical condition (able to perform self-care) **You may NOT be eligible if...** - You have more than 20 brain metastases - You have previously had radiation to the brain - Your lung cancer has spread to the fluid surrounding the brain (leptomeningeal disease) - Your overall health is too poor to tolerate the procedure - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONStereotactic Radiosurgery

All participants will undergo MSK standard SRS. A CT simulation will be performed per institutional standards, typically with contrast unless a contraindication exists. A contrast-enhanced MRI with 1mm slices will be fused to the CT simulation scan for the purposes of SRS planning. The SRS GTV will be considered the visible tumor on MRI and CT contrast enhanced studies. An expansion of 1-2mm will be used to create the PTV. Radiation dose may be between 16Gy and 30Gy in 1 to 5 fractions, per the discretion of the treating radiation oncologist. Participants with multiple lesions may receive different doses to each lesion per the discretion of the treating radiation oncologist. Concurrent treatment to other body sites is permitted.

PROCEDURECerebrospinal fluid collection

All participants will undergo lumbar puncture for CSF collection at study enrollment.. Lumbar punctures will be performed by clinical staff in neurology or neuroradiology, per the discretion of the treating radiation oncologist, as dictated by scheduling limitations and expected clinical difficulty in obtaining a sample (e.g. requiring fluoroscopic guidance), with input from the PI, neurology, and/or neuroradiology as necessary. Participants will be encouraged to undergo repeat lumbar puncture for CSF collection at 3 months (+/- 4 weeks), and at the time of CNS disease progression, though these latter timepoints are not required. CSF cytology will be evaluated.